Author Correction: The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort.
Sci Rep. 2020 Nov 13; 10(1):20199.SR

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Links

Authors+Show Affiliations

National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan. Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Chiang NJ

Tsai HJ

Yen CJ

Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Shan YS

Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. ysshan@mail.ncku.edu.tw. College of Medicine, National Cheng Kung University, Tainan, Taiwan. ysshan@mail.ncku.edu.tw.

Chen LT

National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan. Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Department of Internal Medicine, Kaohsiung Medical University Hospital and Kaohsiung Medical University, Kaohsiung, Taiwan.

Pub Type(s)

Published Erratum

Language

eng

PubMed ID

33188263

Citation

Su, Yung-Yeh, et al. "Author Correction: the Impact of Liposomal Irinotecan On the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort." Scientific Reports, vol. 10, no. 1, 2020, p. 20199.

Su YY, Chiang NJ, Tsai HJ, et al. Author Correction: The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort. Sci Rep. 2020;10(1):20199.

Su, Y. Y., Chiang, N. J., Tsai, H. J., Yen, C. J., Shan, Y. S., & Chen, L. T. (2020). Author Correction: The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort. Scientific Reports, 10(1), 20199. https://doi.org/10.1038/s41598-020-77250-4

Su YY, et al. Author Correction: the Impact of Liposomal Irinotecan On the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort. Sci Rep. 2020 Nov 13;10(1):20199. PubMed PMID: 33188263.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Author Correction: The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort. AU - Su,Yung-Yeh, AU - Chiang,Nai-Jung, AU - Tsai,Hui-Jen, AU - Yen,Chia-Jui, AU - Shan,Yan-Shen, AU - Chen,Li-Tzong, Y1 - 2020/11/13/ PY - 2020/11/14/entrez PY - 2020/11/15/pubmed PY - 2020/11/15/medline SP - 20199 EP - 20199 JF - Scientific reports JO - Sci Rep VL - 10 IS - 1 N2 - An amendment to this paper has been published and can be accessed via a link at the top of the paper. SN - 2045-2322 UR - https://www.unboundmedicine.com/medline/citation/33188263/Author_Correction:_The_Impact_of_Liposomal_Irinotecan_on_the_Treatment_of_Advanced_Pancreatic_Adenocarcinoma:_Real_World_Experience_in_a_Taiwanese_Cohort_ DB - PRIME DP - Unbound Medicine ER -

Tags

Author Correction: The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort.Sci Rep. 2020 Nov 13; 10(1):20199.SR